



NeuroScientific
BIOPHARMACEUTICALS

NOVEL DRUG THERAPIES FOR
NEURODEGENERATIVE CONDITIONS

INVESTOR UPDATE

SEPTEMBER 2022 • ASX: NSB

neuroscientific.com

DISCLAIMER



The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.




NSB INVESTOR UPDATE ON EMTINB™ HREC SUBMISSION

STRUCTURAL FORMULA OF EMTINB™



Figure 1 Structural formula of EmtinB



EmtinB™ is a peptide derived from Metallothionien-II

HREC SUBMISSION REFUSED ON THREE MATTERS



NSB understands the HREC decision. The HREC explained the three reasons for the refusal were safety, purity of EmtinB™ and efficacy.

- **Safety**– local injection site tolerability was not satisfactorily demonstrated, with systemic safety not noted as a concern.
- **Purity of EmtinB™** – lack of clear identification of impurities and overall purity of the product was questioned. Peptide manufacturing is complex and holds no clear guidance on overall purity requirements.
- **Efficacy** – Key efficacy animal model was not accepted due to a different form of the EmtinB being used in this study from planned clinical product.

NSB NEXT STEPS FOR EMTINB™ (3-6 months)




- **Safety.** Two independent toxicologists (one US board certified and one with both US and EU board certification) to perform a thorough GAP analysis. Following completion of all required toxicology, a formal independent toxicology report opinion will be provided for revised HREC submission.
- **Purity of EmtinB™:** Currently in discussion with two manufacturers regarding the further purification of available GMP material and full characterization of impurities. The Company is also conducting a full CMC regulatory GAP analysis.
- **Efficacy.** NSB will present efficacy data on the preclinical multiple sclerosis model. The data and the final report are due from the external provider by 28 February 2023.

NSB NEXT STEPS FOR EMTINB™ (3–6 months)



- **Interim CEO:** Potential to appoint an interim CEO to oversee the next 3–6 months.
- **Potential new asset licensed into NSB:** The Company plans to file at least 2 new patents on EmtinB and potentially licensed in a new technology to expand the Company's pipeline.
- **Re-submission plans:** Once all items of concern that were raised through our initial submission attempt are satisfactorily addressed, and confirmed through independent expert review, NSB will re-submit to the Australian HREC or an alternant Geography, such as the MHRA (UK), to undertake the Phase I clinical trial.



NeuroScientific
BIOPHARMACEUTICALS

neuroscientific.com

For more information contact:

Paul Rennie– Chairman

E: ir@neuroscientific.com